Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06698796 |
| Consolidated Lead Sponsor | Pfizer |
| Therapeutic Condition Cohort | Rare Genetic, Women's Health, and Other |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 211 participants (ESTIMATED) |
| Registered Start Date | 2025-01-22 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Anhui Provincial Hospital | Hefei, China | Open Hospital Dossier -> |
| The Second Affiliated Hospital of Nanchang University | Nanchang, China | Open Hospital Dossier -> |
| Peking Union Medical College Hospital | Beijing, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.